{"id":34434,"date":"2025-05-29T17:07:03","date_gmt":"2025-05-29T09:07:03","guid":{"rendered":"https:\/\/flcube.com\/?p=34434"},"modified":"2025-05-29T17:07:04","modified_gmt":"2025-05-29T09:07:04","slug":"bms-gains-european-approval-for-opdivo-subcutaneous-formulation","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34434","title":{"rendered":"BMS Gains European Approval for Opdivo Subcutaneous Formulation"},"content":{"rendered":"\n

Bristol-Myers Squibb (BMS; NYSE: BMY<\/a>) announced that the European Commission (EC) has granted approval to the subcutaneous (SC) injection formulation of Opdivo (nivolumab) for the treatment of multiple adult solid tumors. The approved indications encompass Opdivo SC, co-formulated with recombinant human hyaluronidase (rHuPH20), for use as a monotherapy, maintenance monotherapy following combined intravenous (IV) Opdivo and Yervoy (ipilimumab) treatment, or in combination with chemotherapy or cabozantinib.<\/p>\n\n\n\n

Approval Backed by Clinical Data<\/strong>
The positive decision from the EC was based on results from the CheckMate-67T clinical trial and additional supporting data. The trial demonstrated comparable pharmacokinetics (PK) and safety profiles between Opdivo SC and IV-administered Opdivo. Specifically, in adults with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who had received no more than two prior systemic therapies and no prior immuno-oncology treatment, Opdivo SC met the primary PK endpoints of non-inferiority compared to IV Opdivo in Cavgd28 (28-day average steady-state concentration) and Cminss (steady-state trough concentration).<\/p>\n\n\n\n

Opdivo SC: A First in the EU<\/strong>
Opdivo SC stands as the only approved subcutaneous PD-1 inhibitor in the European Union. This new formulation offers eligible patients a convenient administration option. Notably, in December 2024, the U.S. Food and Drug Administration (FDA) approved subcutaneous nivolumab and hyaluronidase-nvhy, marketed as Opdivo Qvantig, further expanding the drug’s availability globally.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Bristol-Myers Squibb (BMS; NYSE: BMY) announced that the European Commission (EC) has granted approval to…<\/p>\n","protected":false},"author":1,"featured_media":34435,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[429,428,849,18,15],"class_list":["post-34434","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-bms","tag-bristol-myers-squibb","tag-nyse-bmy","tag-pd-1-l1","tag-product-approvals"],"yoast_head":"\nBMS Gains European Approval for Opdivo Subcutaneous Formulation - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Bristol-Myers Squibb (BMS; NYSE: BMY) announced that the European Commission (EC) has granted approval to the subcutaneous (SC) injection formulation of Opdivo (nivolumab) for the treatment of multiple adult solid tumors. The approved indications encompass Opdivo SC, co-formulated with recombinant human hyaluronidase (rHuPH20), for use as a monotherapy, maintenance monotherapy following combined intravenous (IV) Opdivo and Yervoy (ipilimumab) treatment, or in combination with chemotherapy or cabozantinib.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34434\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BMS Gains European Approval for Opdivo Subcutaneous Formulation\" \/>\n<meta property=\"og:description\" content=\"Bristol-Myers Squibb (BMS; NYSE: BMY) announced that the European Commission (EC) has granted approval to the subcutaneous (SC) injection formulation of Opdivo (nivolumab) for the treatment of multiple adult solid tumors. The approved indications encompass Opdivo SC, co-formulated with recombinant human hyaluronidase (rHuPH20), for use as a monotherapy, maintenance monotherapy following combined intravenous (IV) Opdivo and Yervoy (ipilimumab) treatment, or in combination with chemotherapy or cabozantinib.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34434\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-29T09:07:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-29T09:07:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2910.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34434#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34434\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BMS Gains European Approval for Opdivo Subcutaneous Formulation\",\"datePublished\":\"2025-05-29T09:07:03+00:00\",\"dateModified\":\"2025-05-29T09:07:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34434\"},\"wordCount\":228,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34434#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2910.webp\",\"keywords\":[\"BMS\",\"Bristol-Myers Squibb\",\"NYSE: BMY\",\"PD-1\\\/L1\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34434#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34434\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34434\",\"name\":\"BMS Gains European Approval for Opdivo Subcutaneous Formulation - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34434#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34434#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2910.webp\",\"datePublished\":\"2025-05-29T09:07:03+00:00\",\"dateModified\":\"2025-05-29T09:07:04+00:00\",\"description\":\"Bristol-Myers Squibb (BMS; NYSE: BMY) announced that the European Commission (EC) has granted approval to the subcutaneous (SC) injection formulation of Opdivo (nivolumab) for the treatment of multiple adult solid tumors. The approved indications encompass Opdivo SC, co-formulated with recombinant human hyaluronidase (rHuPH20), for use as a monotherapy, maintenance monotherapy following combined intravenous (IV) Opdivo and Yervoy (ipilimumab) treatment, or in combination with chemotherapy or cabozantinib.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34434#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34434\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34434#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2910.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2910.webp\",\"width\":1080,\"height\":608,\"caption\":\"BMS Gains European Approval for Opdivo Subcutaneous Formulation\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34434#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BMS Gains European Approval for Opdivo Subcutaneous Formulation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BMS Gains European Approval for Opdivo Subcutaneous Formulation - Insight, China's Pharmaceutical Industry","description":"Bristol-Myers Squibb (BMS; NYSE: BMY) announced that the European Commission (EC) has granted approval to the subcutaneous (SC) injection formulation of Opdivo (nivolumab) for the treatment of multiple adult solid tumors. The approved indications encompass Opdivo SC, co-formulated with recombinant human hyaluronidase (rHuPH20), for use as a monotherapy, maintenance monotherapy following combined intravenous (IV) Opdivo and Yervoy (ipilimumab) treatment, or in combination with chemotherapy or cabozantinib.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34434","og_locale":"en_US","og_type":"article","og_title":"BMS Gains European Approval for Opdivo Subcutaneous Formulation","og_description":"Bristol-Myers Squibb (BMS; NYSE: BMY) announced that the European Commission (EC) has granted approval to the subcutaneous (SC) injection formulation of Opdivo (nivolumab) for the treatment of multiple adult solid tumors. The approved indications encompass Opdivo SC, co-formulated with recombinant human hyaluronidase (rHuPH20), for use as a monotherapy, maintenance monotherapy following combined intravenous (IV) Opdivo and Yervoy (ipilimumab) treatment, or in combination with chemotherapy or cabozantinib.","og_url":"https:\/\/flcube.com\/?p=34434","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-29T09:07:03+00:00","article_modified_time":"2025-05-29T09:07:04+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2910.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34434#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34434"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BMS Gains European Approval for Opdivo Subcutaneous Formulation","datePublished":"2025-05-29T09:07:03+00:00","dateModified":"2025-05-29T09:07:04+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34434"},"wordCount":228,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34434#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2910.webp","keywords":["BMS","Bristol-Myers Squibb","NYSE: BMY","PD-1\/L1","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34434#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34434","url":"https:\/\/flcube.com\/?p=34434","name":"BMS Gains European Approval for Opdivo Subcutaneous Formulation - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34434#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34434#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2910.webp","datePublished":"2025-05-29T09:07:03+00:00","dateModified":"2025-05-29T09:07:04+00:00","description":"Bristol-Myers Squibb (BMS; NYSE: BMY) announced that the European Commission (EC) has granted approval to the subcutaneous (SC) injection formulation of Opdivo (nivolumab) for the treatment of multiple adult solid tumors. The approved indications encompass Opdivo SC, co-formulated with recombinant human hyaluronidase (rHuPH20), for use as a monotherapy, maintenance monotherapy following combined intravenous (IV) Opdivo and Yervoy (ipilimumab) treatment, or in combination with chemotherapy or cabozantinib.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34434#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34434"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34434#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2910.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2910.webp","width":1080,"height":608,"caption":"BMS Gains European Approval for Opdivo Subcutaneous Formulation"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34434#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BMS Gains European Approval for Opdivo Subcutaneous Formulation"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2910.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34434","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34434"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34434\/revisions"}],"predecessor-version":[{"id":34436,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34434\/revisions\/34436"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34435"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34434"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34434"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34434"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}